Updates in Therapy for Advanced Melanoma
AbstractCutaneous melanoma is one of the most aggressive forms of skin cancer, and is correlated with a large proportion of skin cancer-related deaths. Therapy for cutaneous melanoma has advanced greatly through careful identification of therapeutic targets and the development of novel immunotherapeutic approaches. The identification of BRAF as well as other driver mutations, have allowed for a specialized approach to treatment. In addition, immune checkpoint inhibition has dramatically changed the treatment landscape over the past 5–10 years. The successful targeting of CTLA-4, as well as PD-1/PD-L1, has been translated into meaningful clinical benefit for patients, with multiple other potential agents in development. Systemic therapy for cutaneous melanoma is becoming more nuanced and often takes a multifaceted strategy. This review aims to discuss the benefits and limitations of current therapies in systemic melanoma treatment as well as areas of future development. View Full-Text
Share & Cite This Article
Singh, B.P.; Salama, A.K.S. Updates in Therapy for Advanced Melanoma. Cancers 2016, 8, 17.
Singh BP, Salama AKS. Updates in Therapy for Advanced Melanoma. Cancers. 2016; 8(1):17.Chicago/Turabian Style
Singh, Bhavana P.; Salama, April K.S. 2016. "Updates in Therapy for Advanced Melanoma." Cancers 8, no. 1: 17.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.